Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib/IIa trial of multiple doses of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome.

Next Previous
Trial Profile

A phase Ib/IIa trial of multiple doses of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Menopausal syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors MenoGeniX

Most Recent Events

  • 03 May 2018 According to a MenoGeniX media release, National Institutes of Health (NIH) has awarded the fund to support this study.
  • 12 Mar 2016 According to the company website, this phase II trial of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome is anticipated to start in 2016.
  • 12 Mar 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top